Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A021602||Alliance||Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091404||Alliance||A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|
|A171901||Alliance||Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice)||Cancer Prevention and Control CIRB||Available to Open|
|A231901CD||Alliance||Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHARES)||Cancer Prevention and Control CIRB||Available to Open|
|A091605||Alliance||A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071102||Alliance||A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221701||Alliance||Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)||Cancer Prevention and Control CIRB||Available to Open|
|A031704||Alliance||PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]||Adult CIRB - Late Phase Emphasis||Available to Open|
|A081801||Alliance||Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO||Adult CIRB - Late Phase Emphasis||Available to Open|
|A021806||Alliance||A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|